Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01125046 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01125046 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 50 participants.
The verdict
NCT01125046, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.
Interventions
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-06-17 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01125046
The ClinicalTrials.gov registry entry for NCT01125046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevacizumab is the first listed.
NCT01125046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01125046 about?
NCT01125046 is a clinical study titled "Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizu...
What is the current status of trial NCT01125046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-06-17. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT01125046?
The interventions under investigation include: bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01125046?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.